- Home
- BH vs RCUS Comparison
BH vs RCUS Comparison
Compare BH & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BH
- RCUS
- Stock Information
- Founded
- BH 1934
- RCUS 2015
- Country
- BH United States
- RCUS United States
- Employees
- BH N/A
- RCUS N/A
- Industry
- BH Restaurants
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- BH Consumer Discretionary
- RCUS Health Care
- Exchange
- BH Nasdaq
- RCUS Nasdaq
- Market Cap
- BH 631.8M
- RCUS 727.1M
- IPO Year
- BH N/A
- RCUS 2018
- Fundamental
- Price
- BH $220.03
- RCUS $7.88
- Analyst Decision
- BH
- RCUS Strong Buy
- Analyst Count
- BH 0
- RCUS 10
- Target Price
- BH N/A
- RCUS $29.50
- AVG Volume (30 Days)
- BH 5.7K
- RCUS 1.2M
- Earning Date
- BH 05-09-2025
- RCUS 05-07-2025
- Dividend Yield
- BH N/A
- RCUS N/A
- EPS Growth
- BH N/A
- RCUS N/A
- EPS
- BH N/A
- RCUS N/A
- Revenue
- BH $362,114,000.00
- RCUS $258,000,000.00
- Revenue This Year
- BH N/A
- RCUS N/A
- Revenue Next Year
- BH N/A
- RCUS $25.77
- P/E Ratio
- BH N/A
- RCUS N/A
- Revenue Growth
- BH N/A
- RCUS 120.51
- 52 Week Low
- BH $159.69
- RCUS $6.50
- 52 Week High
- BH $271.35
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- BH 53.08
- RCUS 44.26
- Support Level
- BH $195.05
- RCUS $6.75
- Resistance Level
- BH $218.76
- RCUS $8.36
- Average True Range (ATR)
- BH 10.13
- RCUS 0.60
- MACD
- BH 1.34
- RCUS 0.16
- Stochastic Oscillator
- BH 91.20
- RCUS 74.19
About BH Biglari Holdings Inc. Class B
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, Oil and Gas Operations. Company's restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The Company also reports segment information for Maxim. The majority of revenue is derived from the Maxim Segment.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.